Latham & Watkins Advises Alpha Tau Medical in US$36.9 Million Registered Direct Offering

Latham & Watkins has advised Alpha Tau Medical Ltd. (Alpha Tau), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, on the purchase and sale of 14,110,121 ordinary shares to an affiliate of Oramed Pharmaceuticals Inc. at a purchase price of US$2.612 per ordinary shares. The offering closed on April 28, 2025. The total gross proceeds of the offering were approximately US$36.9 million, before deducting estimated offering expenses payable by Alpha Tau.

The Latham team was led by London partner Joshua Kiernan and Tel Aviv counsel Michael Rosenberg, with Tel Aviv associate Jamie Savren. Advice was also provided on tax matters by Century City partner Pardis Zomorodi, with associate Sam Yang.